Impact of mycophenolate mofetil dose posttransplantation on 12-month renal function: analysis of the MOST database.

Abstract Introduction Mycophenolate mofetil (MMF) has greatly reduced the risk of acute rejection episodes (ARE) after renal transplantation, but dose reductions/withdrawals could jeopardize long-term results. Methods The MOST database of “de novo” patients treated with MMF at month 1 and functioning grafts at month 12 were divided into 2 groups: groups 1, 2 g MMF at month 1 and month 12; and group 2, 2 g MMF at month 1 but MMF Results In this study, 1136 patients were receiving 2 g MMF at month 1. On month 12, 645 were on 2 g (56.8%, group 1) and 431 were on P = .05 at month 12). GFR in group 1 and group 2 were 59.06 (CI 57.10–60.60) and 53.81 (CI 52–55.7) at month 1 ( P 2 at month 12 ( P 2 , respectively ( P Conclusions Maintenance of MMF dose at 2 g/d during the first year appears to facilitate the attainment of optimal renal function at 12-months after kidney transplantation.